CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
US Dollar Holds Near One-Week High as Middle East Tensions and Oil Prices Drive Market Sentiment 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
ASEAN Ministers Warn Middle East Conflict Threatens Regional Stability and Energy Security 
Trump Administration Releases New UFO Files and Apollo Mission Records 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
